Business Wire

SAMSUNG-ELECTRONICS

Share
Samsung Brings Advanced Ultra-Fine Pixel Technologies to New Mobile Image Sensors

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced the ISOCELL HP1, the industry’s first 200-megapixel (MP) image sensor with 0.64μm pixels, and ISOCELL GN5, the first image sensor to adopt all-directional focusing Dual Pixel Pro technology with two photodiodes in a single 1.0μm pixel.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005321/en/

“Samsung has been pioneering ultrafine pixel technologies that are taking high-resolution image sensors to the next level,” said Duckhyun Chang, executive vice president of sensor business at Samsung Electronics. “With the ISOCELL HP1 that is breaking barriers and ISOCELL GN5 bringing ultrafast auto focus, Samsung will continue to lead the trend for next-generation mobile imaging technologies.”

ISOCELL HP1: Capture the world in breathtaking 200MP and crystal sharp 8K video

The ISOCELL HP1 is the industry’s first mobile image sensor to support 200MP. Based on Samsung’s most advanced 0.64μm-sized pixels, the ISOCELL HP1 brings such ultrahigh resolution in a small package that fits comfortably in today’s handheld devices. With the ISOCELL HP1, pictures hold an astonishing amount of detail that helps the image stay sharp even when cropped or resized.

For ultimate low-light photography, the ISOCELL HP1 features an all-new ChameleonCell technology, a pixel-binning technology that uses a two-by-two, four-by-four or full pixel layout depending on the environment. In a low-lit environment, the HP1 transforms into a 12.5MP image sensor with large 2.56μm pixels by merging 16 neighboring pixels. The newly formed 2.56μm pixel is capable of more light absorption and sensitivity, producing brighter and clearer photos in in-doors or in the evening. In bright outdoor environments, the sensor’s 200-million pixels can capture ultra-high-definition photography on mobile devices.

The ISOCELL HP1 can take 8K videos at 30 frames-per-second (fps) with minimum loss in the field of view. The HP1 merges four neighboring pixels to bring the resolution down to 50MP or 8,192 x 6,144 to take 8K (7,680 x 4,320) videos without the need to crop or scale down the full image resolution.

ISOCELL GN5: Lock on instantly and take super-sharp hi-res images with all-directional autofocus

The ISOCELL GN5 is the industry’s first 1.0μm image sensor to integrate Dual Pixel Pro, an all-directional autofocusing technology, that can substantially boost autofocusing capabilities. This technology places two photodiodes, the smallest in the industry, within each 1.0μm pixel of the sensor either horizontally or vertically to recognize pattern changes in all directions. With one million phase-detecting multi-directional photodiodes covering all areas of the sensor, the ISOCELL GN5’s autofocusing becomes instantaneous, enabling sharper images in either bright or low-lit environments.

The image sensor also makes use of Samsung’s proprietary pixel technology, which applies Front Deep Trench Isolation (FDTI) on a Dual Pixel product for the first time in the industry. Despite the microscopic photodiode size, FDTI enables each photodiode to absorb and hold more light information, improving the photodiodes’ full-well capacity (FWC) and decreasing crosstalk within the pixel.

Samples of Samsung ISOCELL HP1 and GN5 are currently available.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com .

* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0μm-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. Samsung continues to enhance its pixel isolation methods with ISOCELL Plus and ISOCELL 2.0 technologies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye